The sphingosine kinase activator K6PC-5 stimulates C2C12 myoblast differentiation

8Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Previously, K6PC-5, a synthetic derivative of ceramide, was demonstrated to activate sphingosine kinase (SK)-1 in keratinocytes. In this study its potential biological effect in mouse myoblasts was examined. The obtained results show that K6PC-5 promotes myogenic differentiation by enhancing myogenic marker expression, differentiation index and fusion index. Interestingly, its biological action was prevented by pharmacological inhibition of SK or S1P 2 receptor, in full agreement with their recognized role in myoblast differentiation. This is the first evidence that pharmacological activation of SK accelerates myogenesis and suggests that this new therapeutic strategy could be possibly employed in skeletal muscle disorders where muscle regeneration is deficient. Copyright © by BIOLIFE, s.a.s.

Cite

CITATION STYLE

APA

Bernacchioni, C., Cencetti, F., Kwon, M. J., Gwak, H. S., Jeong, S. K., Bruni, P., & Donati, C. (2011). The sphingosine kinase activator K6PC-5 stimulates C2C12 myoblast differentiation. International Journal of Immunopathology and Pharmacology, 24(1), 55–62. https://doi.org/10.1177/039463201102400107

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free